Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

被引：25
|
作者：
Luke, J.
Rutkowski, P.
Queirolo, P.
Del Vecchio, M.
Mackiewicz, J.
Sileni, V. Chiarion
De la CruzMerino, L.
Khattak, M. A.
Schadendorf, D.
Long, G. V.
Ascierto, P. A.
Mandala, M.
De Galitiis, F.
Sondak, V.
Scolyer, R. A.
Kirkwood, J. M.
Chen, K.
Ibrahim, N.
Ahsan, S.
Eggermont, A. M. M.
机构：
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.2116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3
引用
收藏
页码：S1314 / S1315
页数：2
相关论文
共 50 条
  • [41] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
    Buehrer, Emanuel
    Kicinski, Michal
    Mandala, Mario
    Pe, Madeline
    Long, Georgina, V
    Atkinson, Victoria
    Blank, Christian U.
    Haydon, Andrew
    Dalle, Stephane
    Khattak, Adnan
    Carlino, Matteo S.
    Meshcheryakov, Andrey
    Sandhu, Shahneen
    Puig, Susana
    Schadendorf, Dirk
    Jamal, Rahima
    Rutkowski, Piotr
    van den Eertwegh, Alfonsus J. M.
    Coens, Corneel
    Grebennik, Dmitri
    Krepler, Clemens
    Robert, Caroline
    Eggermont, Alexander
    LANCET ONCOLOGY, 2024, 25 (09): : 1202 - 1212
  • [42] Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
    Eggermont, Alexander M. M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew
    Lichinitser, Mikhail
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Di Giacomo, Anna Maria
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul C.
    Lupinacci, Robert
    Krepler, Clemens
    Ibrahim, Nageatte
    Kicinski, Michal
    Marreaud, Sandrine
    van Akkooi, Alexander C.
    Suciu, Stefan
    Robert, Caroline
    EUROPEAN JOURNAL OF CANCER, 2019, 116 : 148 - 157
  • [43] KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2-breast cancer
    Cardoso, F.
    Bardia, A.
    Andre, F.
    Cescon, D. W.
    McArthur, H.
    Telli, M.
    Loi, S.
    Cortes, J.
    Schmid, P.
    Harbeck, N.
    Denkert, C.
    Jackisch, C.
    Jia, L.
    Tryfonidis, K.
    Karantza, V.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] RESULTS FROM A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL ON PERIOPERATIVE EFFICACY AND SAFETY OF BIPOLAR VERSUS MONOPOLAR TRANSURETHRAL RESECTION OF THE PROSTATE
    Mamoulakis, C.
    Skolarikos, A.
    Schulze, M.
    Scoffone, M.
    Rassweiler, J.
    Alivizatos, G.
    Scarpa, M.
    De La Rosette, J. J. M. C. H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 62 - 62
  • [45] Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma
    Ryoo, Baek-Yeol
    Palmer, Daniel H.
    Park, Sook Ryun
    Rimassa, Lorenza
    Sarker, Debashis
    Daniele, Bruno
    Steinberg, Joyce
    Lopez, Beatriz
    Lim, Ho Yeong
    CLINICAL DRUG INVESTIGATION, 2021, 41 (09) : 795 - 808
  • [46] Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma
    Baek-Yeol Ryoo
    Daniel H. Palmer
    Sook Ryun Park
    Lorenza Rimassa
    Bruno Debashis Sarker
    Joyce Daniele
    Beatriz Steinberg
    Ho Yeong López
    Clinical Drug Investigation, 2021, 41 : 795 - 808
  • [47] ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
    Wu, Yi-Long
    Herbst, Roy S.
    Mann, Helen
    Rukazenkov, Yuri
    Marotti, Marcelo
    Tsuboi, Masahiro
    CLINICAL LUNG CANCER, 2018, 19 (04) : E533 - E536
  • [48] Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Lorusso, Domenica
    Xiang, Yang
    Hasegawa, Kosei
    Scambia, Giovanni
    Leiva, Manuel
    Ramos-Elias, Pier
    Acevedo, Alejandro
    Cvek, Jakub
    Randall, Leslie
    Gomes, Andrea Juliana Pereira de Santana
    Mejia, Fernando Contreras
    Helpman, Limor
    Akilli, Huseyin
    Lee, Jung-Yun
    Saevets, Valeriya
    Zagouri, Flora
    Gilbert, Lucy
    Sehouli, Jalid
    Tharavichitkul, Ekkasit
    Lindemann, Kristina
    Colombo, Nicoletta
    Chang, Chih-Long
    Bednarikova, Marketa
    Zhu, Hong
    Oaknin, Ana
    Christiaens, Melissa
    Petru, Edgar
    Usami, Tomoka
    Liu, Peng
    Yamada, Karin
    Toker, Sarper
    Keefe, Stephen M.
    Pignata, Sandro
    Duska, Linda R.
    LANCET, 2024, 404 (10460): : 1321 - 1332
  • [49] KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2-breast cancer
    Cardoso, F.
    Bardia, A.
    Andre, F.
    Cescon, D. W.
    McArthur, H.
    Telli, M.
    Loi, S.
    Cortes, J.
    Schmid, P.
    Harbeck, N.
    Denkert, C.
    Jackisch, C.
    Jia, L.
    Hirshfield, K.
    Karantza, V.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Thomalla, Goetz
    Bonekamp, Susanne
    Fiehler, Jens
    Bendszus, Martin
    LANCET, 2024, 404 (10464): : 1730 - 1730
12345